DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
"Receiving orphan drug designation from the FDA is a significant milestone for DiagnaMed and validates the promise of molecular hydrogen as a potential treatment for ALS. We are excited to partner ...
Green Market Report12d
Revive Therapeutics buys DiagnaMed’s molecular hydrogen intellectual property
In addition to the patent, Revive also gets the intellectual and work property derived from DiagnaMed’s research activities ...
Revive Therapeutics enters LOI to acquire DiagnaMed’s molecular hydrogen program
Revive Therapeutics (RVVTF) has entered into a non-binding letter of intent, dated February 28, 2025, to acquire the full rights to DiagnaMed ...